Hepatocellular carcinoma (HCC) is the second most common cause of cancer deaths worldwide, with 800,000 deaths per year. Since surgical options for HCC patients are limited, minimally invasive ablative therapies are critical to treat early-stage HCC; however, their cost and need for specialized equipment and expertise prevent widespread use in underprivileged populations. Here, we propose a lower-cost Light-Activatable, Sustained-exposure Ethanol Injection Technology (LASEIT) to augment current options for underprivileged patients.
|